EGFR and non-small cell lung carcinoma: Consistently, Wang et al. collected 61 NSCLC patients with BM, and found that mutations in major drivers, including EGFR, KRAS, TP53, and ALK, were highly concordant between primary tumors and matched BMs (>80%)11.